Summary
Synopsis: Synopsis: Tolmetin1 (1-methyl-5-p-toluoylpyrrole-2-acetic acid) is a new non-steroidal anti-inflammatory, antipyretic and analgesic agent advocated for use in rheumatoid arthritis, juvenile rheumatoid arthritis, degenerative joint disease and ankylosing spondylitis.
Published data suggest that in rheumatoid arthritis, tolmetin 1200 to 1600mg daily is comparable in effectiveness with about one-eighth its dose of indomethacin and with moderate to high doses of aspirin (4 to 4.5g daily), but generally causes fewer and less troublesome side-effects at the dosages used. Tolmetin appears to be comparable with alclofenac 4g daily, and at least as effective as ibuprofen, but has not been compared with the other commonly used phenylalkanoic acid derivatives such as naproxen and fenoprofen. However, as no one of the non-steroidal anti-inflammatory agents is the most suitable drug for all patients requiring such therapy, tolmetin should be considered along with the other drugs of its type in the initial treatment of the arthritic patient. Tolmetin, as a pyrole acetic acid derivative like indomethacin, has compared favourably with indomethacin in degenerative joint disease and anky losing spondylitis*, but it is generally better tolerated than indomethacin in the diseases studied.
Pharmacology: In experimental studies in animals, tolmetin has been shown to inhibit rat paw oedema caused by carrageenan or kaolin and to inhibit joint and inflammatory changes in established adjuvant-induced arthritis. In guinea-pigs, tolmetin delayed the appearance of ultraviolet-induced erythema.
Tolmetin is a potent inhibitor of bovine seminal vesicle prostaglandin synthesis in vitro.
The antipyretic effect of tolmetin has been demonstrated in rats with yeast-induced hyperthermia, and the analgesic effect in patients with pain of varying origin.
Tolmetin, like many other non-steroidal anti-inflammatory agents, produces lesions in the mucosa of the stomach and small intestine. However, this effect is less marked than with aspirin or indomethacin.
In healthy volunteers, tolmetin 1200mg daily causes less gastrointestinal bleeding than therapeutically equivalent doses of aspirin given for the same period. Tolmetin has not been compared in this regard with other commonly used non-steroidal anti-inflammatory agents other than indomethacin, or with other forms of aspirin.
Tolmetin has a mild antiplatelet effect similar to that found with aspirin, but the duration of effect after discontinuation is shorter with tolmetin than with aspirin. Unlike aspirin, tolmetin has only a slight effect on platelet adhesiveness.
Pharmacokinetic studies indicate that in humans, tolmetin is rapidly and almost completely absorbed after oral administration. Peak plasma concentrations are generally attained 20 to 60 minutes and are dose related. Like the phenylalkanoic acid derivatives, tolmetin is highly bound to serum protein and has a fairly low apparent volume of distribution.
Tolmetin is quickly cleared from the plasma, mainly by metabolism, and has an elimination half-life of about 60 minutes based on the assumption that pharmacokinetics are linear. However, use of a nonlinear model results in a half-1 ife of about 5 hours. The principal metabolite, the decarboxylic acid, has no apparent anti-inflammatory activity in animals.
In arthritic patients the rate constants for drug absorption and elimination are not significantly different from those in normal subjects, but the area under the plasma level curve profile is lower in arthritic patients than in healthy volunteers.
Therapeutic Trials: In the treatment of rheumatoid arthritis, tolmetin has been compared in formal comparative trials with placebo, high dose aspirin, indomethacin and phenylbutazone and other non-steroidal anti-inflammatory agents including alclofenac and ibuprofen. Tolmetin has invariably been shown to be superior to placebo. In all but one of the studies comparing tolmetin and aspirin, there has been no significant difference between the drugs with regard to effectiveness, but side-effects have been less frequent with tolmetin. Similarly, there was no significant difference between tolmetin 800 to 1400mg daily and indomethacin 100 to 150mg daily, or between tolmetin 1600mg daily and phenylbutazone 400mg daily, but tolmetin was generally better tolerated than the reference drugs.
Tolmetin was comparable with alclofenac in one study and with ibuprofen in another, but was rated superior to ibuprofen in a retrospective comparison.
There appeared to be little therapeutic advantage in treatment with a combination of tolmetin and aspirin compared with aspirin alone, but tolmetin plus paracetamol was shown to be superior to tolmetin alone on the basis of subjective assessment. However, this advantage was less evident when assessed by objective and semi-objective criteria. Similarly, a gold-tolmetin combination was considered by investigators and patients to be superior to gold alone, but the combination produced significantly greater improvement in only a minority of more objective criteria.
The addition of tolmetin to stabilised doses of prednisone enabled a significant reduction in the daily dose of the corticosteroid and also resulted in greater symptomatic improvement. Although the addition of tolmetin to a fixed dose of oral corticosteroid resulted in a higher proportion of satisfactory responses than the corticosteroid alone, there was a tendency towards a higher incidence of side-effects with the combination treatment.
Long-term open studies indicated that a progressive improvement in joint symptoms and some objective measurements of disease activity can be achieved in patients treated for 12 months or more with usual dosages.
In degenerative joint disease involving the hip and knee,* there was no significant difference in the efficacy of tolmetin 600 to 1200mg daily and indomethacin 75 to 150mg or aspirin 4.5g daily, although patients and physicians preferred tolmetin to aspirin and indomethacin tended to be more effective than tolmetin in relieving hip pain.
Tolmetin has been shown to be at least as effective as indomethacin (at about one-eighth the dose) in patients with definite ankylosing spondylitis*, but tolmetin has yet to be compared with the phenylalkanoic acid derivatives in this condition.
Results of a well conducted study in juvenile rheumatoid arthritis found no significant differences in the clinical responses to aspirin or tolmetin over a 12-week period.
Side-effects: At dosages usually used in the treatment of rheumatic diseases, tolmetin has generally been well tolerated during short-term and long-term studies. The overall incidence of side-effects has been 25 to 40% of patients treated with 1200 to 1600mg daily. In controlled studies side-effects have necessitated withdrawal of treatment in about 5 to 8 % of patients. Gastrointestinal effects such as epigastric pain, dyspepsia, nausea and vomiting have been the most frequently reported adverse reactions but have generally been less troublesome with tolmetin than with aspirin. Peptic ulceration and upper gastrointestinal bleeding have been reported occasionally. Central nervous system effects have generally occurred less frequently than gastrointestinal effects, but have been less of a problem than with indomethacin. Tinnitis, deafness, dizziness and vertigo have occurred more frequently with aspirin than with tolmetin.
Drug Interactions: Although tolmetin, like the phenylalkanoic acid derivatives is highly bound to plasma protein and has a low volume of distribution, studies specifically designed to determine the likelihood of interaction with warfarin, phenprocoumon and glibenclamide, have found no evidence of clinically significant interaction. Absorption of tolmetin is not influenced by concomitant administration of an antacid containing magnesium-aluminium hydroxide gel.
Laboratory Test Modifications: The metabolites of tolmetin cause false positive tests for proteinuria when the tests rely on acid precipitation (e.g. sulfosalicylic acid method). No interference has been noted in tests that use dye-impregnated, commercially available reagent strips.
Dosage: The usual initial adult dose is 1200mg daily in three or four divided doses**. The dosage schedule includes a dose on arising and at bedtime. However, dosage should be adjusted according to individual response. Control is usually achieved at a dosage of 600 to 1800mg daily. The recommended initial dose in children is 20mg/kg daily in divided doses. The dosage should be adjusted according to individual response, control usually being achieved at doses of 15 to 30mg/kg daily.
Similar content being viewed by others
References
April, P.; Albert, M.; Deighton, M.N. and Termulo, C.: Comparison of tolmetin with aspirin in the treatment of rheumatoid arthritis; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Awouters, F.; Niemegeers, C.J.E. and Lenaerts, F.M.: The effects of suprofen in rats with mycobacterium butyricum-induced arthritis. Arzneimittel-Forschung 25: 1526 (1975b)
Awouters, F.; Niemegeers, C.J.E.; Lenaerts, P.M.H. and Janssen, P.A.: Suprofen, a potent antagonist of ultraviolet-erythema in guinea-pigs. Arzneimittel-Forschung 25: 1509 (1975a)
Aylward, M.; Holly, F.; Maddock, J. and Wheeldon, R.: Treatment of rheumatoid arthritis with tolmetin: a comparison with alclofenac. Current Medical Research and Opinion 4: 695 (1977)
Aylward, M.; Maddock, J.; Parker, R.J.; Thomas, S.R. and Holly, F.: Evaluation of tolmetin in the treatment of active chronic rheumatoid arthritis: open and controlled double-blind studies. Current Medical Research and Opinion 4: 158 (1976)
Ayres, J.W.; Weidler, DJ.; Mackichan, J.; Sakmar, E.; Hallmark, M.R.; Lemanowicz, E.F. and Wagner, J.G.: Pharmacokinetics * * The usual dose in Japan is approximately one half that in the USA. of tolmetin with and without concomitant administration of antacid in man. European Journal of Clinical Pharmacology 12: 421 (1977a)
Ayres, J.W.; Weidler, D.J.; Sakmar, E. and Wagner, J.G.: Linear and nonlinear assessment of tolmetin pharmacokinetics. Research Communications in Chemical Pathology and Pharmacology 17: 583 (1977b)
Bachmann, F.; Stroescu, 01 and Hartl, W.: Double-blind and dose range studies with tolectin in rheumatoid arthritis. Zeitschrift fur Allgemeinmedizin/Der Landarzt (Stuttgart) 30: 1382 (1975)
Bain, L.S.; El-Ghobarey, A.F.; Collins, R.M. and Sargent, N.W.: Tolmetin: an evaluation of a new preparation in the treatment of rheumatoid arthritis. British Journal of Clinical Practice 29: 208 (1975)
Beirne, J.A.; Bianchine, J.R.; Johnson, P. and Wortham, G.F.: Gastrointestinal blood loss caused by tolmetin, aspirin and indomethacin. Clinical Pharmacology and Therapeutics 16: 821 (1974)
Bernhard, G.C.; Poiley, J. and Tarpley, E.L.: A double-blind cooperative trial of tolmetin plus gold in the treatment of rheumatoid arthritis; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Berkowitz, S.S.; Bernhard, G.; Bilka, P.J.; Blechman, W.J.; Marchesano, J.M.; Rosenthal, M. and Wortham, G.F.: Tolmetin versus placebo for the treatment of rheumatoid arthritis: a sequential double-blind clinical trial. Current Therapeutic Research 16: 442 (1974)
Brown, J.H.; Hull, J. and Biundo, J.J.: Results of a one-year trial of tolmetin in patients with rheumatoid arthritis. Journal of Clinical Pharmacology 15: 455 (1975)
Brown, J.R. and Weir, A.B. Jnr.: Drug fever from tolmetin administration. Letter to Editor. Journal of the American Medical Association 239: 24 (1978)
Caldwell, J.; Brandon, M.L.; Franz, K.H.; Clark, G.M. and Ricca, L.R.: A comparison of the efficacy and side-effect liability of tolmetin and indomethacin; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Cardoe, N. and Steel, C.E.: A double-blind crossover comparison of tolmetin sodium and phenylbutazone in the treatment of rheumatoid arthritis. Current Medical Research and Opinion 4: 688 (1977)
Carson, J.R.; McKinstry, D.N. and Wong, S.: 5-Benzoyl-1-methylpyrrole-2-acetic acids as anti-inflammatory agents. Journal of Medicinal Chemistry 14: 646 (1971)
Chalmers, A.; Offer, R.C. and Robinson, H.S.: Combined therapy with aspirin and tolmetin in rheumatoid arthritis. Arthritis and Rheumatism 18: 392 (1975)
Chlud, K. and Kaik, B.: Clinical studies of the interaction between tolmetin and glibenclamide. International Journal of Clinical Pharmacology 15: 409 (1977)
Clark, G.M.; Ricca, L.R. and Albert, M.: Evaluation of tolmetin in the treatment of rheumatoid arthritis not responding to ibuprofen. Current Therapeutic Research 21: 697 (1977)
Clerck, F. De; Vermylen, J. and Reneman, R.: Effects of suprofen, an inhibitor of prostaglandin biosynthesis, on platelet function, plasma coagulation and flbrinolysis. 1. In vitro experiments. Archives Internationales de Physiologie et de Biochimie 216: 263 (1975)
Cressman, W.A.; Wortham, G.F. and Plostnieks, J.: Absorption and excretion of tolmetin in man. Clinical Pharmacology and Therapeutics 19: 224 (1976)
Duckert, F.: Tolectin administration to anticoagulated patients and coagulation parameters. Absence of interference. VIII European Rheumatology Congress, Helsinki June 1–7 1975, Scandinavian Journal of Rheumatology 4: S10–02 Supplement 8 (1975)
Ehrlich, G.E. and Wortham, G.F.: Pseudoproteinuria in tolmetin-treated patients. Clinical Pharmacology and Therapeutics 17: 467 (1975)
Ehrlich, G.E. and Roth, S.: Rheumatoid arthritis: long-term therapy with tolmetin sodium. Orthopedics Digest 4: 16 (1976)
Ehrlich, G.E.; Hobbs, T.R.; Cordrey, L.J. and Hamaty, D.: Tolmetin: long-term therapy in patients with rheumatoid arthritis; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Freeman, A.M.; Golding, D.N. and Steele, C.E.: A double-blind crossover study comparing tolmetin and indomethacin in the treatment of rheumatoid arthritis. Current Medical Research and Opinion 5: 262 (1977)
Huskisson, E.C.; Berry, H.; Scott, J. and Bahne, H.W.: Tolectin for rheumatoid arthritis. Rheumatology and Rehabilitation 13: 132 (1974)
Johnson, P.C.; Binachine, J.R.; Bierne, J. and Wortham, G.F.: Gastrointestinal blood loss produced by tolmetin, aspirin and indomethacin as measured by the 51Cr technique. Clinical Research 22: 642 (1974)
Johnson, P.C.; Lidsky, M. and Amadio, P.: Evaluation of the endocrine system response to tolmetin in patients with acute rheumatoid arthritis; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Klemp, P. and Meyers, O.L.: Clinical trial of tolmetin and aspirin in the treatment of rheumatoid arthritis. South African Medical Journal 52: 167 (1977)
Levinson, J.E.; Baum, J.; Brewer, E.; Fink, C.W.; Hanson, V. and Schaller, J.: Comparison of tolmetin and aspirin in the treatment of juvenile rheumatoid arthritis. Journal of Pediatrics 91: 799 (1977)
McMillen, J.I.: Tolmetin sodium vs ibuprofen in rheumatoid arthritic patients previously untreated with either drug: A double-blind crossover study. Current Therapeutic Research 22: 266 (1977)
Maibach, E.: The treatment of extra-articular rheumatic diseases and fresh distortions with Tolectin (R). Therapiewoche 27: 2318 (1977)
Maibach, H. and Kram, J.: The effect of tolmetin on immediate and delayed hypersensitivity skin reactions; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent, p. 174, (Excerpta Medica, Princeton 1975)
Mann, N.S.: Drug induced acute erosive gastritis. American Journal of Proctology 28: 23 (1977)
Manz, G. and Franke, M.: The treatment of ankylosing spondylitis with Tolectin (R) and indomethacin. A randomised double-blind study. Therapiewoche 27: 2288 (1977)
Mielke, GH.; Heiden, D. and Amadio, P.: Tolmetin: hematological effects in normal subjects; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Miller, J.L.: Tolmetin sodium. Arthritis and Rheumatism 20: 1033 (1977)
Muller, F.O.; Gosling, J.A. and Erdmann, G.H.: A comparison of tolmetin with aspirin in the treatment of osteo-arthritis of the knee. South African Medical Journal 51: 794 (1977)
Niemegeers, C.J.E.; Lenaerts, F.M. and Janssen, P.A.J.: The antipyretic effect of suprofen in rats with yeast-induced fever. Arzneimittel-Forschung 25: 1519 (1975)
Noordewier, B.; Stygles, V.G.; Hook, J.B. and Gussin, R.Z.: Effect of tolmetin on renal function and prostaglandin metabolism. Journal of Pharmacology and Experimental Therapeutics 204: 461 (1978)
Pavelka, K. and Susta, A.: Tolmetin, a new non-steroidal anti-rheumatic. Arzneimittel-Forschung 24: 1353 (1974)
Pavelka, K. and Susta, A.: Treatment of osteoarthrosis with tolmetin — a new nonsteroidal antirheumatic agent. Drugs under Experimental and Clinical Research 2: 67 (1977)
Plostnieks, J.; Cressman, W.A.; Lemanowicz, E.F.; Migdalof, B.H. and Tarn, J.J.S.: Human metabolism of tolmetin; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Rau, R.; Lobsiger, M. and Gross, D.: Tolmetin treatment in patients with osteoarthritis of the hip and the knee. VIII European Rheumatology Congress, Helsinki June 1–7 1975. Scand. J. Rheumatol. 4: S10–12 Supplement 8 (1975)
Rau, R.; Lobsiger, M. and Gross, D.: Treatment of severe osteoarthrosis of the knee and the hip with tolmetin. (A double-blind comparison with indomethacin). Praxis 66: 147 (1977)
Robinson, H.; Abruzzo, J.L.; Miyara, A. and Ward, J.R.: Concomitant tolmetin and aspirin therapy for rheumatoid arthritis; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Romanowica, A. and MacCagno, A.: Tolectin in rheumatoid arthritis. XIII International Congress of Rheumatology, Kyoto, Japan Sept. 30–Oct 6 1973. Excerpta Medica. International Congress Series No. 299, p.l 13 (1973)
Roth, S.H. and Simson, J.: Steroid therapy combined with tolmetin or placebo in the treatment of rheumatoid arthritis: a double-blind co-operative trial; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Roth, S.H.; Englund, D.W.; Harris, B.K. and Ross, H.A.: The anti-inflammatory activity of tolmetin with acetaminophen in the treatment of rheumatoid arthritis; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Rotstein, J.: A comparative study of tolmetin versus placebo in the treatment of rheumatoid arthritis; in: Ward (Ed) Tolmetin A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica 1975)
Rust, O.; Biland, L.; Thilo, D.; Nyman, D. and Duckert, F.: Testing of the antirheumatic drug tolmetin for interaction with oral anticoagulants. Schweizerische Medizinische Wochenschrift 105: 752 (1975)
Schattenkirchner, M.; Schattenkirchner, U. and Muller-Fassbender, A.: Clinical experience with Tolectin® in the long-term treatment of ankylosing spondylitis. Therapiewoche 27: 2298 (1977)
Schneyer, J.J.: Tolmetin versus aspirin in the treatment of rheumatoid arthritis: a controlled double-blind study, in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Selley, M.L.; Thomas, J. and Triggs, E.J.: A gas-liquid Chromatographic method for the quantitative determination of tolmetin in plasma and tolmetin and its major metabolite in urine. Journal of Chromatography 94: 143 (1974)
Selley, M.L.; Glass, J.; Triggs, E.J. and Thomas, J.: Pharmacokinetic studies of tolmetin in man. Clinical Pharmacology and Therapeutics 17: 599 (1975)
Setoyama, M. and Nagase, M.: Analgesic effect of tolmetin in surgical patients. Basic Pharmacology and Therapeutics 4: 193 (1976)
Shriver, D.A.; White, C.B.; Sandor, A. and Rosenthale, M.E.: A profile of the rat gastrointestinal toxicity of drugs used to treat inflammatory diseases. Toxicology and Applied Pharmacology 32: 73 (1975)
Silvestri, N. and Perrotta, P.: Valutazione dell’attivita terapeutica di unnouvo farmaco antiflogistico non steroides, Tolectin, nell’artrite reumatoide. IL Farmaco 32: 319 (1977)
Sofia, R.D.; Knobloch, L.C. and Vassar, H.B.: Inhibition of the primary lesion of adjuvant-induced polyarthritis in rats (18-hour arthritis test) for specific detection of clinically effective antiarthritic drugs. Journal of Pharmacology and Experimental Therapeutics 193: 918 (1975)
Strandel, W.: The question of the drug treatment of ankylosing spondylitis. Therapiewoche 27: 2273 (1977)
Sumner, D.D.; Dayton, P.G.; Cucinell, S.A. and Plostnieks, J.: Metabolism of tolmetin in rat, monkey and man. Drug Metabolism and Disposition 3: 283 (1975)
Taylor, R.J. and Salata, J.J.: Inhibition of prostaglandin synthetase by tolmetin (tolectin, MCN-2559), a new non-steroidal anti-inflammatory agent Biochemical Pharmacology 25: 2479 (1976)
Wax, J.; Winder, C.V.; Tessman, D.K. and Stephens, M.D.: Comparative activities, tolerance and safety of non-steroidal anti-inflammatory agents in rats. Journal of Pharmacology and Experimental Therapeutics 192: 172 (1975)
Whitsett, T.L.; Barry, J.P.; Czerwinski, A.W. etal.: Interaction of tolmetin and warfarin: a clinical investigation; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Wong, S.; Gardocki, J.F. and Pruss, T.P.: Pharmacologic evaluation of tolectin (tolmetin, MCN-2559) and MCN-2891, two anti-inflammatory agents. Journal of Pharmacology and Experimental Therapeutics 185: 127 (1973)
Wong, S.: Chemistry and Pharmacology of tolmetin, 1-methyl-5-p-toluoylpyrrole-2-acetic acid; in Ward (Ed) Tolmetin: A New Non-Steroidal Anti-Inflammatory Agent (Excerpta Medica, Princeton 1975)
Author information
Authors and Affiliations
Additional information
Manuscript reviewed by: N. Cardoe, Norfolk and Norwich Hospital, Norfolk, England; G.E. Ehrlich, Albert Einstein Medical Center, Philadelphia, USA; F.D. Hart Harley Street, London, England; E.C. Huskisson, Department of Rheumatology, St. Bartholomew’s Hospital, London, England; P. Klemp, Rheumatic Diseases Unit, Groote Schuur Hospital, South Africa; J.J. McMillen, Camp Hill, Pennsylvania, USA; S.H. Roth, Phoenix Arthritis Center, Arizona, USA.
Tolectin (McNeil, Ethnor, Ortho, Cilag-Chemie).
In the USA, tolmetin is approved for use only in the treatment of rheumatoid arthritis and juvenile rheumatoid arthritis.
In the USA, tolmetin is approved for use only in the treatment of rheumatoid arthritis and juvenile rheumatoid arthritis.
Rights and permissions
About this article
Cite this article
Brogden, R.N., Heel, R.C., Speight, T.M. et al. Tolmetin: A Review of its Pharmacological Properties and Therapeutic Efficacy in Rheumatic Diseases. Drugs 15, 429–450 (1978). https://doi.org/10.2165/00003495-197815060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-197815060-00002